Navigation Links
Liquid Tissue(R) Patent Licensed for Amyloidosis Proteomic Assay
Date:11/17/2009

ROCKVILLE, Md., Nov. 17 /PRNewswire/ -- Expression Pathology, a leader in tissue proteomic analysis, today announced Mayo Clinic has licensed non-exclusive rights to Expression Pathology's Liquid Tissue® patent for use in diagnosis of systemic amyloidosis in formalin-fixed tissue.

Patented Liquid Tissue® methodology enables solubilization of proteins for mass spectrometric analysis of formalin-fixed paraffin-embedded (FFPE) tissue, the standard form of preserved patient tissue used in clinical pathology testing worldwide. Mayo Clinic has applied the technology to develop a specific and sensitive mass spectrometry based method for diagnosis and classification of amyloidosis in routine biopsy specimens, in a format that is rapid and readily applicable in a clinical setting. This test is being offered to patients worldwide through Mayo Medical Laboratories, Mayo Clinic's reference laboratory.

With 50,000 diagnosed cases every year worldwide amyloidosis can be a localized or systemic disease, characterized by organ function impairment, sometimes as severe as cardiac and/or renal failure. Subtyping of cases is critical as management of the disease differs radically, from drug therapies to major organ transplants.

The new Liquid Tissue-based method aids in treatment decisions as it exhibits greater sensitivity and specificity than the traditional IHC based classification. In an early case study of 56 FFPE cardiac biopsies involving amyloidosis immunohistochemistry was diagnostic in 19/52 cases and equivocal in 33/52 cases (4 cases no IHC). The mass spectrometry-based Liquid Tissue method identified the amyloidosis type in 53 of 56 cases studied.

"Detailed mass spectrometry analysis of proteins related to specific disease conditions in FFPE tissue is opening huge opportunities in personalized medicine to relate those measurements to patient treatment decisions," said Casey Eitner, President and CEO of Expression Pathology. "We are delighted that Mayo Clinic has applied our Liquid Tissue® methodology to solve a difficult medical problem."

Financial terms of the agreement were not disclosed.

About Mayo Medical Laboratories

Mayo Clinic offers proven diagnostic tests to more than 5,000 health care institutions around the world through Mayo Medical Laboratories, Mayo Clinic's reference laboratory. Revenue from Mayo Medical Laboratories' testing is used to support medical education and research at Mayo Clinic. www.MayoMedicalLaboratories.com

About Expression Pathology Inc.

Expression Pathology Inc., Rockville, MD, has developed proprietary techniques for discovery and quantitative analysis of protein biomarkers in FFPE tissue. The company's Director® laser microdissection slides enable precise, rapid, automated collection of specific cellular features from tumor tissue. Its Liquid Tissue® reagents and technology make possible discovery and measurement of proteins in FFPE tissue by mass spectrometry. EPI employs its Liquid Tissue® proteomics platform in its own and collaborative assay development and biomarker discovery programs, and offers contract research services and products. For more information, please visit www.expressionpathology.com.

    Expression Pathology contact:

    Peter Tunon
    VP Sales and Marketing
    Expression Pathology Inc.
    9620 Medical Center Drive
    Rockville, MD 20850
    301.977.3654
    Email p.tunon@expressionpathology.com

SOURCE Expression Pathology Inc.


'/>"/>
SOURCE Expression Pathology Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Baxter and The Alzheimers Disease Cooperative Study Group to Pursue a Phase III Study of Gammagard Liquid in Patients With Alzheimers Disease
2. Baxter Presents Latest Clinical Trial Results of GAMMAGARD LIQUID Administered Subcutaneously
3. Study Results of GAMMAGARD S/D and GAMMAGARD LIQUID in Patients with Mild-to-Moderate Alzheimers Disease Announced
4. Advocate Christ Medical Center Using Glue-Like Liquid to Seal Off Brain Aneurysms
5. New Data Demonstrates 5-FU Personalized Chemotherapy Management (PCM(R)) Assay Provides Similar Performance to More Complicated Liquid Chromatography-Mass Spectrometry (LC-MS/MS)
6. NeurogesX Initiates Dosing in Phase 1 Clinical Trial for NGX-1998 Capsaicin Liquid Formulation
7. White Paper Explains Aspects of Testing From Purified Bulk Drug Substance to Sterile Liquid Final Drug Product
8. Xanodyne Expands U.S. Sales Force and Launches Zipsor(TM) (diclofenac potassium) Liquid Filled Capsules
9. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
10. ArtJen Announces Major Clinical Trial of Its Patented Weight Loss Product FBCx
11. FAU Receives Patent for Invention Which Induces and Restores Cardiac Muscle Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016  Global Blood Therapeutics, Inc. (GBT) ... developing novel therapeutics for the treatment of grievous ... the closing of its previously announced underwritten public ... the public offering price of $18.75 per share. ... offered by GBT. GBT estimates net proceeds from ...
(Date:6/24/2016)... 24, 2016 Research and ... "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" report ... In-Mold Electronics, Smart Skin, Structural Health Monitoring, ... Structural electronics involves electronic and/or electrical components ... replacing dumb structures such as vehicle bodies or ...
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June 24, 2016 ... mobile pulmonary function testing company, is now able to perform sophisticated ... by ndd Medical Technologies , Inc. Patients ... hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ARL patients ... get any needed testing done in the comfort of her own ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their ... Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. , ... Pro X users can now reveal the media of their split screens with ...
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, and ... in the eye of the beholder, according to experts who offered insights and commentary ... of Managed Care. For the full issue, click here . , For the ...
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
Breaking Medicine News(10 mins):